SNT Syntara Limited
—Mkt Cap: —P/E: —1d ago
Syntara Limited, a clinical-stage drug development company, that targets extracellular matrix dysfunction through amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions…
Industry Peers
Drug Manufacturers - GeneralKey Statistics
Company
Market Cap—
Enterprise Value20.46M USD
Revenue (TTM)4.79M USD
Gross Profit-310.99K USD
Net Income (TTM)-6.64M USD
Revenue/Share0.0040 AUD
Last Price—
Fiscal Year EndJun 2026
MR QuarterJun 2026
Employees—
CountryAU
SectorHealthcare
IndustryDrug Manufacturers - General
ISINAU0000312480
Valuation
P/E (Trailing)—
P/E (Forward)-7.00
PEG2.49
EV/EBITDA-3.11
EV/Revenue4.27
P/S5.95
P/B2.62
EPS (TTM)-0.01
EPS (Forward)-0.00
52W Range
—
52W High—
52W Low—
Profitability
Gross Margin-6.49%
Oper. Margin-95.99%
EBITDA Margin-137.51%
Profit Margin-129.78%
ROE-59.65%
ROA-29.81%
Growth
Revenue Growth-13.30%
Earnings Growth—
Cash Flow & Leverage
Operating CF-6.76M USD
CapEx (TTM)—
FCF Margin-96.74%
FCF Yield—
Net Debt-9.37M USD
Net Debt/EBITDA1.42
Balance Sheet
Debt/Equity0.01
Current Ratio6.57
Quick Ratio6.42
Book Value/Sh0.0080 AUD
Cash/Share0.0070 AUD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 AUD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)0.1050 AUD
Target Range0.0600 AUD – 0.1500 AUD
# Analysts2
Ownership
Shares Out.1.96B
Float1.53B
Insiders27.40%
Institutions15.29%
Technical
SMA 500.0246 AUD
SMA 2000.0277 AUD
Beta0.24
S&P 52W Chg16.44%
Avg Vol (30d)—
Avg Vol (10d)2.88M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—